Download ZOOM ON: Breast cancer: what`s new?

NEWSLETTER n°3 - March 2017
www.imodi-cancer.org
ZOOM ON: Breast cancer: what’s new?
• NEWS: Big pharma acquire a new collection of PDX
• IMODI around the world: Meet the experts!
• FOCUS on: The Leon Berard Clinical Center
ZOOM
• ADVERT: A new web catalogue for IMODI products
Breast cancer: what’s new?
Therapeutic management of metastatic breast cancers is drastically changing. Recent
evidence from extensive prospective clinical studies has demonstrated the efficacy of
treatments combining endocrine therapies and other targeted therapies, which now
become standard treatments.
Among these targeted therapies, the PI3K-AKT-mTOR pathway inhibition is the treatment of
choice in a progressive disease under endocrine therapy. More recently, the association with
CDK4/6 inhibitors is progressively becoming a treatment of choice for hormone-dependent
metastatic cancers.
Despite recent advances in precision medicine, the known activating mutations of PIK3CA gene,
as well as CCND1 gene amplifications or p16 gene losses, are not associated with response
to treatments using inhibitors of these pathways. Moreover, subtypes of breast tumors that do not express hormone receptors and
HER2 protein (triple negative subtype), are challenging tumors as endocrine and targeted therapies are non effective.
Dr Olivier Tredan, Medical Oncologist
at the Leon Berard Clinical Center
For these reasons, it is mandatory to identify new targets and predictive biomarkers to better select patients and thus prescribe
adapted and targeted therapies.
More about
NEWS
Servier, Pierre Fabre and Sanofi acquire a new collection of patient-derived
xenograft (PDX) models for their translational breast cancer research.
Servier, Pierre Fabre and Sanofi, 3 out of 4 major pharmaceutical companies involved in
the IMODI consortium, have a new collection of PDX models to support their translational
breast cancer research. This new collection represents 40 established breast PDX models
reflecting the 4 major molecular clinical subtypes among which 37% are triple negative, 33%
are Luminal B HER2 -, 22% are Luminal B HER2+ and 8% HER2+. All PDX models are
well-characterized and annotated under harmonized procedures by the IMODI consortium.
More about
IMODI
AROUND THE WORLD
Meet the experts
Discover next representations on main international events
Dr Séverine Tabone-Eglinger (Leon Berard clinical center) will present Innovative and predictive
models against breast cancer. Minisymposium session Models for Treatment Resistance and Drug
Discovery at the AACR Annual meeting (Tuesday Apr 4, 2017 3:00 PM). >>>
Dr Juan Iovanna (Inserm U1068, Marseille, France) will present a poster of IMODI initiative : a
novel holistic and integrative approach with patient-derived tumor models against pancreatic cancer:
poster presentation in the tumor biology poster session, abstract #3846 at the AACR A nnual meeting
(Tuesday Apr 4, 2017 8:00 AM). >>>
More about
Next >
Page 1 on 2
www.imodi-cancer.org - [email protected]
© IMODI Cancer - March 2017 - All right reserved -
NEWSLETTER n°3 - March 2017
The Leon Berard Clinical Center:
Research and Innovation for better Cancer Patient Care
The Leon Berard Clinical
Center
(CLB)
is
an
integrated cancer research
center relying on the
excellence of the basic
research conducted at
the
Cancer
Research
Center in Lyon (CRCL), a
high quality translational research labeled by the SIRIC
program of INCa (LYric) and an efficient clinical research
labelled ISO 9001 since July 2013. The translational
research department gathers technological platforms, such
as the biological resource center - certified NFS 96 900,
a pathology department dedicated to research, the cancer
genomics platform, the immunomonitoring platform and
the ex-vivo platform, which all contribute to accelerate the
transfer of innovations of its research programs to the clinic.
ADVERT
FOCUS
www.imodi-cancer.org
The CLB is one of the founders, along with Claude Bernard
University, INSERM and the Hospices Civils de Lyon,
of the scientific cooperation foundation created in 2007,
Synergie Lyon Cancer (SLC). Through its missions, the
SLC Foundation supports research activity carried out in
Lyon in the field of tumor escape and therapeutic targeting.
It is composed of three technological platforms: 1) the
laboratory of experimental models (LMT) dedicated to
establish panels of relevant tumor models in oncology; 2)
the bioinformatics platform Gilles Thomas with recognized
expertise in Whole Genome Sequencing; 3) the Drug
Discovery and Development Center, which promotes the
development of molecules derived from the basic research
of the Leon Berard Clinical Center or the CRCL.
(Read full article on IMODI website)
More about
A new web catalogue for IMODI products
The IMODI website offers you a free web-catalogue of products developed by the
consortium.
Discover more details about our 107 new models in the beta version of the web catalogue.
Next version will include more information about cell lines, ex vivo assays and bio-collection.
The IMODI catalogue is daily optimized and updated to offer you more and efficient services.
More about
What about IMODI
www.imodi-cancer.org
The french IMODI (Innovative MODels Initiative) consortium is dedicated to the development,
the characterization and the commercialization of new preclinical models in oncology.
IMODI is a public-private consortium of 18 partners pooling their ressources for the development
of more valuable models of cancer in order to decrease the attrition rate of clinical development
of novel anti-cancer agents.
Model and treat
the diversity of cancers
Science and technology developments:
2013/01/01: Creation of the consortium
2013/09/01: Signature of the consortium
agreement
Designed by: Essentiel MARKETING
2015/10/01: Signature of the 1st licence
agreement
7 years: duration of the 1rst R&D phase
Developing PDX models
and cellular assays
Modelling the human tumour
microenvironment in mice
Studying the relationship
between microbiota and cancer
IMODI’s partners
150 Researchers
6 SMEs
4 pharmaceutical industries
8 Academic institutions
www.imodi-cancer.org - [email protected]
© IMODI Cancer - March 2017 - All rights reserved -